Headache News

BOSTON — Intranasal Zavzpret was safe and effective for acute treatment of migraine, providing pain relief as early as 15 minutes after administration, according to a presenter at the American Academy of Neurology annual meeting.

BOSTON — Headache-related quality of life lagged clinical improvement in headaches for individuals with long COVID at 12 to 19 months, according to a poster from the American Academy of Neurology annual meeting.

BOSTON — Fewer patients who took ubrogepant during the premonitory phase went on to have headache when compared with placebo, Peter Goadsby, MD, PhD, FRS, said in this Healio video at the American Academy of Neurology annual meeting.

As allergies emerge each spring, so do migraines. The American Migraine Foundation says that 37% of people with allergies also have migraines, compared with 5% of people who do not have allergies, in an association that increases with age.

BOSTON – Treatment with once-daily atogepant significantly reduced monthly migraine days in adults with episodic migraine compared with placebo, according to preliminary data presented at the American Academy of Neurology annual meeting.

The FDA has approved expanding the indication of Qulipta, an oral calcitonin gene-related peptide receptor antagonist, for preventing migraine in adults.

The FDA approval of Zavzpret, which Pfizer announced in March 2023, is good news for people living with migraine, as it becomes an important option to help combat this disease.

Treatment with zavegepant 10 mg nasal spray was safe, well-tolerated and provided pain and symptom relief for moderate to severe migraine compared with placebo, according to a study published in The Lancet Neurology.

The FDA has approved Pfizer’s Zavzpret, a calcitonin gene-related peptide receptor antagonist nasal spray to treat migraine with or without aura in adults.

Perceived stress was associated with both prevalent and incident cognitive function impairment in Black and white older adults, underlining the need for stress assessments among high-risk adults in primary care, according to researchers.